Non-Small Cell Lung Cancer (Second Line or Beyond)
For the treatment of patients with metastatic NSCLC whose tumours express PD-L1 (as determined by a validated test) and who have disease progression on or after platinum-containing chemotherapy. Funding is being requested for patients with a TPS (Tumour Proportion Score) of PD-L1 ≥1%.
Merck Canada Inc.
Submission Deemed Complete:
Requested and Granted
Stakeholder Input Deadline ‡:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Reimburse with clinical criteria and/or conditions
‡ Patient Advocacy Groups (or individual patients and caregivers
when there is no patient group) and Clinicians who are registered
with pCODR are eligible to provide Input and Feedback.
Deadlines for Input and Feedback are by the end of the pCODR business day
(5P.M. Eastern Time) of the date noted.